Abstracts tagged "rituximab and sample size"

Abstract Number: 2880 • 2013 ACR/ARHP Annual Meeting
Impact Of Different End Points On The Patient Cohort Size Needed To Demonstrate The Efficacy Of a Therapeutic Intervention In Pss. A Post Hoc Analysis Of The Tears Study (Tolerance and efficacy of Rituximab in primary Sjogren Syndrome study)
Valerie devauchelle-Pensec¹, Sandrine jousse-Joulin², Xavier Mariette³, Jean-Marie Berthelot⁴, Aleth Perdriger⁵, Eric Hachulla⁶, Xavier Puechal⁷, Véronique le Guern⁸, Jean Sibilia⁹, Jacques-Eric Gottenberg¹⁰, Laurent Chiche Sr.¹¹, Vincent Goeb¹², Gilles Hayem¹³, Jacques Morel¹⁴, Charles Zarnitsky¹⁵, Jean Jacques Dubost¹⁶, Jacques-Olivier Pers¹⁷, Divi Cornec¹⁸, Raphaèle Seror¹⁹, Emmanuel Nowak²⁰ and Alain Saraux²¹, ¹Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France, ²Rheumatology/Immunology, CHU de la Cavale Blanche, Brest, France, ³Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France, ⁴Rheumatology Unit, Nantes University Hospital, Nantes, France, ⁵Rheumatology, Hôpital Sud, Rennes, France, ⁶Internal Medicine, Lille CEDEX, France, ⁷Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁸Department of Internal Medicine, Hôpital Cochin, Paris, France, ⁹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹⁰Strasbourg University Hospital, Strasbourg, France, ¹¹Internal Medicine, CHU Marseille, Marseille, France, ¹²Rheumatology, Amiens University Hospital, Amiens, France, ¹³Rheumatology Unit, Bichat Hospital, Paris, France, ¹⁴Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ¹⁵Rheumatology, Le Havre General Hospital, Le Havre, France, ¹⁶Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ¹⁷Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, ¹⁸Department of rheumatology, Brest Occidentale University, Brest, France, ¹⁹Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ²⁰CIC, CHU Brest, Brest, France, ²¹Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France
Background/Purpose: To calculate the sample sizes needed in future randomized controlled trials (RCTs) testing a therapeutic intervention in pSS, methodologists usually rely on data obtained…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].